Cargando…
Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?
INTRODUCTION: Botulinum toxin (BoNT) is the treatment of choice for many neurologic movement disorders, including blepharospasm, hemifacial spasm, and cervical dystonia. There are two serotypes approved for use by the US Food and Drug Administration: three brands of serotype A and one of serotype B....
Autores principales: | Fraint, Avram, Vittal, Padmaja, Comella, Cynthia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751901/ https://www.ncbi.nlm.nih.gov/pubmed/26917963 http://dx.doi.org/10.2147/TCRM.S99239 |
Ejemplares similares
-
New observations in the fragile X-associated tremor/ataxia syndrome (FXTAS) phenotype
por: Fraint, Avram, et al.
Publicado: (2014) -
Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia
por: Fernandez, Hubert H., et al.
Publicado: (2013) -
Italian botulinum toxin network recommendations for safe treatment of botulinum toxin infiltration during the COVID-19 pandemic: A video presentation
por: Bono, Francesco, et al.
Publicado: (2021) -
Ultrasonographic Considerations for Safe and Efficient Botulinum Neurotoxin Injection in Masseteric Hypertrophy
por: Lee, Hyung-Jin, et al.
Publicado: (2021) -
Botulinum Toxin in Pediatric Neurology: Switching Lanes From Death to Life
por: Moawad, Eman M. I., et al.
Publicado: (2015)